Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients
Information source: Seoul National University Hospital
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: lacidipine (4 mg) or losartan (50 mg) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Seoul National University Hospital Official(s) and/or principal investigator(s): Cheol-Ho Kim, MD, PhD, Principal Investigator, Affiliation: Seoul National University Bundang Hospital
Overall contact: Cheol-Ho Kim, MD, PhD, Phone: 82-31-787-7001, Email: cheolkim@snu.ac.kr
Summary
The aim of this study is to evaluate the effect of lacidipine and losartan in elderly
hypertensive patients on reducing the 24 hour systolic BP variability, which is one of the
potential parameter to consider in treating elderly hypertensive patients.
Clinical Details
Study design: Treatment, Randomized, Open Label, Parallel Assignment
Primary outcome: The change of 24-hour, one day systolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and losartan group
Secondary outcome: The change of 24-hour, one day diastolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and losartan groupThe difference of the changes in office diastolic and systolic BP after 12 weeks' treatment between lacidipine group and losartan group The difference of the mean 24-hour ABPM systolic and diastolic BP after 12 weeks' treatment between lacidipine group and losartan group The difference of the diastolic and systolic BP control rates after treatment between the 2 groups The difference of the changes in 24-hour, one day BP standard deviation (SD) within subjects between lacidipine group and losartan group The difference of the variation of coefficient (CV) of the mean values (24-hour BP SD divided by the mean multiplied by 100) between 2 groups The difference of the smoothness index (SI, dividing the average of the 24 hourly change after treatment by the corresponding standard deviation) between 2 groups The difference of the changes in pulse pressure after treatment between the 2 groups
Detailed description:
In this study, we investigate the effects of two anti-hypertensive medications on systolic
BP variability profile as a pilot study. This is a prospective, randomized, open-label,
blinded end point (PROBE), parallel group study with two treatment arms. At the end of an
initial 2-week washout period, during which any eventual anti-hypertensive drug is
discontinued, patients fulfilling the inclusion criteria are randomly treated with the
lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning
(approximately at 8 AM) for 12 weeks. If the BP goal (SBP < 140 mmHg and DBP < 90 mmHg) has
not been attained after 4 week's treatment, 12. 5 mg hydrochlorothiazide (HCTS) once daily
can be added.
Patients are checked 24-h ambulatory BP monitoring (ABPM) at the end of the washout period
and after 12 weeks of active treatment. At each visit, seated cuff SBP and DBP, heart rate,
use of concomitant medication and spontaneously reported adverse events are recorded.
Eligibility
Minimum age: 65 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Elderly patients (age > 65 years)
- Essential hypertension (systolic BP > 140 mmHg or diastolic BP > 90 mm Hg)
- Provide written informed content
Exclusion Criteria:
- Secondary hypertension
- Myocardial infarction or cerebrovascular accident within the preceding 6 months
- Clinically significant valvular heart disease, heart failure (Class III, IV), renal
insufficiency (serum creatinine > 2. 5mg/dl), hepatic failure, uncontrolled diabetes
mellitus
- Known hypersensitivity to the drugs used in the study.
Locations and Contacts
Cheol-Ho Kim, MD, PhD, Phone: 82-31-787-7001, Email: cheolkim@snu.ac.kr
Seoul National University Bundang Hospital, Seongnam, Kyeonggi 463-707, Korea, Republic of; Recruiting Cheol-Ho Kim, MD, PhD, Phone: 82-31-787-7001, Email: cheolkim@snu.ac.kr
Additional Information
Starting date: September 2007
Ending date: September 2008
Last updated: October 18, 2008
|